A Pharmacokinetic and Bioavailability Study of Mannitol for Inhalation Using Normal Subjects

Healthy Volunteers Clinical Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00446771
• Other study ID #: DPM-PK-101
• Status: Completed
• Phase: Phase 1
• First received: March 12, 2007
• Last updated: March 12, 2007
• Start date: October 2006
• Est. completion date: November 2006

Study information

• Verified date: March 2007
• Source: Pharmaxis
• Contact: n/a
• Is FDA regulated: No
• Health authority: Australia: Department of Health and Ageing Therapeutic Goods Administration
• Study type: Interventional

Clinical Trial Summary

The study has an open-label, randomized, crossover design, in which each subject will receive mannitol powder for inhalation using a dry powder inhaler with and without premedication with a bronchodilator, mannitol powder for inhalation in capsules administered orally, and mannitol in a commercial formulation designed for intravenous use.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 18
• Est. completion date: November 2006
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Subject has signed a written informed consent form.

• Subject is a normal male volunteer between 18 and 65 years of age.

• Subject is willing to comply with the procedures of the study and to remain in the clinical unit for the scheduled visits.

• Subject is willing to abstain from chewing gum for the duration of the study.

Exclusion Criteria:

• Subject has asthma or other disease affecting the lungs or airways.

• Subject has a history indicating possible airway hyperresponsiveness.

• Subject is allergic to mannitol or gelatin or a known intolerance to intravenous mannitol.

• Subject uses inhaled drugs (legal or illegal).

• Subject uses oral bronchodilator drugs.

• Subject has celiac disease, Crohn's disease or other disease affecting intestinal absorption.

• Subject has renal impairment or other condition that would affect urine collection.

• Subject's weight deviates by more than 15% from the ideal weight listed for his height in the Metropolitan Life table.

• Subject is a smoker.

• Subject has participated in another clinical trial within the past 30 days.

• Subject has used chewing gum within the past 72 hours.

• Subject needs to use bisphosphonates, non-steroidal anti-inflammatory agents, or other drugs known to affect intestinal permeability on a chronic basis.

• Subject has used non-steroidal anti-inflammatory agents within the past 72 hours

Study Design

Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Healthy Volunteers

Intervention

Drug:
• Mannitol

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Pharmaxis

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To determine the absolute bioavailability of mannitol powder for inhalation by comparison to mannitol administered intravenously.
Primary	To determine the relative bioavailability of mannitol powder for inhalation by comparison to orally administered mannitol.
Primary	To determine the pharmacokinetic parameters of systemically available mannitol after administration of mannitol powder by inhalation.
Secondary	A secondary objective of the study is to provide information on the urinary excretion of mannitol after each of the routes of administration.